Drugs / MK-8325
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01554189 | Apr 2012 → Apr 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8325 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01554189 ↗ |
| Route | Oral | “MK-8325 capsules, orally” NCT01554189 ↗ |